Long-acting injectable antiretroviral therapy (ART) can be administered at home to persons living with HIV as safely and effectively by a health care professional as in the clinic, with equally high ...

WHO’s 2025 HIV clinical guidelines simplify and strengthen care by recommending more durable, safer treatment regimens, ...

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully passed an ...

Knowable Magazine reports on breakthroughs in HIV treatment; engineered antibodies show promise for long-term control, ...

Viral suppression is one of the major goals of the Centers for Disease Control and Prevention (CDC) Ending the HIV Epidemic in the US (EHE) initiative. 1 Viral suppression is defined in this context ...

The Purpose 1 trial with 5,000 participants took place at three sites in Uganda and 25 sites in South Africa to test the efficacy of lenacapavir and two other drugs. Lenacapavir (Len LA) is a fusion ...

The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...

Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported from the drugmaker Gilead Sciences, who found two annual injections of the ...

A few weeks ago, Grant Ogren and Rhea Ashby-Durall, the executive director and the outreach manager of SAN (formerly Spokane AIDS Network), met with their representative from Gilead Sciences, the ...

Twice-yearly shots used to treat AIDS were 100% effective in preventing new infections in women, according to a new study. There were no infections among the young women and girls who received the ...

A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic ...